Ryan Nelson
Editor-in-Chief, Medtech Insight, HBW Insight
Ryan has been covering the medical device and consumer health, wellness and beauty sectors since 2004, first as a reporter for Gray Sheet, where he covered beats including Capitol Hill, international and emerging technology, and then as managing editor of Rose Sheet. In his current role, he oversees and heads up strategy for their successor publications Medtech Insight and HBW Insight. He also manages and contributes regularly to HBW Insight’s Beauty channel with a focus on regulatory, policy and legal issues and has moderated related panels at industry events. Ryan has a growing role in developing podcasts, new features, “deep dive” article series, and infographics across teams and publications. Off the job, he enjoys spending time with his wife Katie, son Finn and daughter Maggie in Alexandria, VA, a DC suburb.
Latest From Ryan Nelson
ECHA Committees Get Started On PFAS Opinions, Armed With More Than 5,600 Comments
The agency’s committees for Risk Assessment and Socio-Economic Analysis will check comments and take relevant evidence-based information into consideration as they develop their opinions. Final opinions will be delivered to the European Commission “in the shortest possible timeframe,” ECHA says.
FDA’s Linda Katz Takes MoCRA Questions At IBA Regulatory Workshop
The director of FDA’s Office of Cosmetics and Colors addressed questions on the responsible person required by the Modernization of Cosmetics Regulations Act, safety substantiation, adverse event reporting and more at the IBA virtual event.
Cosmetics Europe Expanding To Meet Historic Challenges: ‘There’s Never Been A Time Like This’
Director-general John Chave discusses regulatory heavy-handedness in the EU, implications for animal testing, declining European investment, and Cosmetics Europe’s message to policymakers going into the 2024 EU elections and beyond.
Akili Turns Heel, Goes ‘All In’ On OTC Model For ADHD Digital Therapeutics
The Boston, MA-based company says the pivot away from Rx will enable it to pursue a significantly larger market and remove “key friction points” that have prevented patients from accessing its game-based digital ADHD treatment. The company is targeting year-over-year cost savings of $8m-$18m after investments to juice up its direct digital marketing program.
Akili Turns Heel, Goes ‘All In’ On OTC Model For ADHD Digital Therapeutics
The Boston, MA-based company says the pivot away from Rx will enable it to pursue a significantly larger market and remove “key friction points” that have prevented patients from accessing its game-based digital ADHD treatment. The company is targeting year-over-year cost savings of $8m-$18m after investments to juice up its direct digital marketing program.
‘Fully Caffeinated’ Or Not, EU’s Revision Of Cosmetic Products Regulation In Doubt Before 2024 Elections
The European Commission’s proposal for revising the EU’s regulation on cosmetic products is likely to release in the 2023 fourth quarter as a “caffeinated or slightly decaffeinated” distillation of the Chemicals Strategy for Sustainability, Cosmetics Europe director-general John Chave says. Prospects for the proposed regulation are questionable in light of EU elections slated for June 2024.